The Cooper Companies, Inc. $COO Stock Position Lifted by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC increased its stake in The Cooper Companies by 13.9% during Q1, now owning 312,650 shares, which represents about 3.1% of its portfolio.
• Cooper Companies reported $1.10 earnings per share for the quarter, exceeding analysts' expectations of $1.07, along with a revenue of $1.06 billion.
• Analysts have mixed ratings on the stock, with recent price targets ranging from $66.00 to $92.00, reflecting a consensus average rating of "Moderate Buy" and a target price of $86.64.

Parkman Healthcare Partners LLC lifted its position in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 13.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 312,650 shares of the medical device company's stock after purchasing an additional 38,081 shares during the quarter. Cooper Companies comprises approximately 3.1% of Parkman Healthcare Partners LLC's portfolio, making the stock its 7th largest holding. Parkman Healthcare Partners LLC owned approximately 0.16% of Cooper Companies worth $26,372,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in shares of Cooper Companies by 21.5% in the 4th quarter. BNP Paribas Financial Markets now owns 344,500 shares of the medical device company's stock valued at $31,670,000 after acquiring an additional 60,979 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Cooper Companies by 19.0% in the fourth quarter. Captrust Financial Advisors now owns 4,542 shares of the medical device company's stock worth $418,000 after purchasing an additional 726 shares during the last quarter. Centiva Capital LP raised its stake in Cooper Companies by 22.2% in the fourth quarter. Centiva Capital LP now owns 5,861 shares of the medical device company's stock valued at $539,000 after purchasing an additional 1,066 shares in the last quarter. Cetera Investment Advisers raised its stake in Cooper Companies by 1.3% in the fourth quarter. Cetera Investment Advisers now owns 24,049 shares of the medical device company's stock valued at $2,211,000 after purchasing an additional 312 shares in the last quarter. Finally, Crestline Management LP bought a new stake in Cooper Companies during the fourth quarter valued at approximately $286,000. Institutional investors own 24.39% of the company's stock.

Analyst Upgrades and Downgrades

COO has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Cooper Companies from $76.00 to $66.00 and set a "neutral" rating on the stock in a report on Thursday, August 28th. Mizuho cut their target price on shares of Cooper Companies from $105.00 to $90.00 and set an "outperform" rating for the company in a research report on Wednesday, July 16th. Piper Sandler lowered their price target on Cooper Companies from $105.00 to $83.00 and set an "overweight" rating on the stock in a research report on Thursday, August 28th. Wells Fargo & Company dropped their price target on Cooper Companies from $93.00 to $72.00 and set an "overweight" rating for the company in a research note on Thursday, August 28th. Finally, UBS Group upgraded Cooper Companies to a "buy" rating in a research report on Tuesday, June 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $86.64.

Cooper Companies Trading Down 0.9%

NASDAQ COO traded down $0.59 during trading on Wednesday, hitting $67.66. 2,397,249 shares of the company's stock traded hands, compared to its average volume of 3,158,719. The stock has a fifty day moving average of $71.85 and a two-hundred day moving average of $76.37. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $112.38. The firm has a market cap of $13.45 billion, a P/E ratio of 33.33, a PEG ratio of 1.73 and a beta of 0.97. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the company posted $0.96 EPS. Cooper Companies's revenue for the quarter was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Insider Activity

In other news, COO Daniel G. Mcbride purchased 3,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was bought at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the acquisition, the chief operating officer directly owned 63,120 shares of the company's stock, valued at $4,105,324.80. This represents a 4.99% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Gerard H. Warner III purchased 1,450 shares of the business's stock in a transaction on Friday, September 5th. The stock was purchased at an average cost of $69.23 per share, for a total transaction of $100,383.50. Following the acquisition, the chief operating officer owned 18,319 shares in the company, valued at approximately $1,268,224.37. The trade was a 8.60% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 15,975 shares of company stock valued at $1,079,566 in the last three months. Corporate insiders own 1.98% of the company's stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.